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Abstract
Background: The therapeutic success of chemotherapeutic agents is often limited by severe adverse effects. To
reduce toxicity of these drugs, nanoscale particle-based drug delivery systems (DDS) are used. DDS accumulate to
some extent in tumor tissues, but only a very small portion of a given dose reaches this target. Accumulation of
DDS in tumor tissues is supposed to be much faster than in certain other tissues in which side effects occur
("Kinetic Targeting”). Once saturation in tumor tissue is achieved, most of the administered DDS still circulate in the
plasma. The extracorporeal elimination of these circulating nanoparticles would probably reduce toxicity.
Methods: For the CARL-trial (Controlled Application and Removal of Liposomal chemotherapeutics), pegylated
liposomal doxorubicin (PLD) was used as chemotherapeutic agent and double filtration plasmapheresis (DFPP) was
performed for extracorporeal elimination of liposomes. PLD was given as 40 mg/m
2 every 3 weeks in combination
with vinorelbine 2 × 25 mg/m
2 (neoadjuvant treatment of breast cancer, 12 patients), or as 40 mg/m
2 every 4
weeks (recurrent ovarian cancer, 3 patients). Primary endpoints were the efficiency and safety profile of DFPP, and
secondary endpoints were side effects and tumor response.
Results: DFPP eliminated ~62% of circulating PLD, corresponding to ~45% of the total dose (n = 57 cycles). AUC
of doxorubicin was reduced by 50%. No leakage of doxorubicin was detected during elimination, and no relevant
DFPP-related side effects occurred. Reduction in tumor size > 30% occurred in 10/12 (neoadjuvant) and in 1/3
patients (recurrent). Only five grade 2 events and one grade 3 event (mucositis, neutropenia or leucopenia) and a
single palmar-plantar erythrodysesthesia grade 2 were reported.
Conclusion: Extracorporeal elimination of PLD by DFPP is safe and efficient. CARL can diminish the main dose-
limiting side effects of PLD, and probably many different DDS alike.
Trial registration: DRKS00000163
Background
The dosing of chemotherapeutic drugs is a delicate balan-
cing act between killing tumor cells and severe toxicity in
other tissues. To reduce the acute adverse effects of toxic
drugs, nanoscale particle-based drug delivery systems
(DDS) are a very promising approach [1]. Liposomal DDS
have been successfully applied in cancer chemotherapy for
over a decade. Their in vivo behavior and pharmacokinetics
are well known [2,3]. Liposomes, like other DDS, accumu-
late in tumor tissues via the enhanced permeation and
retention effect [4]. Peak concentrations of liposomal encap-
sulated chemotherapeutic agents in tumors strongly
depend on their initial plasma concentration [5], and the
average peak plasma concentration of PLD has been found
to correlate closely with the anti-tumor response [6].
In animal models, the elimination of circulating pegylated
liposomal doxorubicin (PLD) in plasma is much faster than
elimination of (liposomal) doxorubicin from tumor tissue
[7]. In humans, a strong signal of liposomal radiotracer was
found in tumor tissue after 7 days, while plasma half-life
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mated as~76 h [8]. Thus minimal or no back diffusion of
PLD from tumor tissue to the plasma compartment can be
assumed. The tumor compartment is usually much smaller
than the plasma or whole body compartment, and despite
accumulation, only a tiny portion of a total dose is detect-
able within the tumor tissue (~0.5 - 3.5% in human tumors
[8]). Considering these facts, it is likely that the vast
amount of administered DDS is only needed to build up a
diffusion gradient between plasma and tumor tissue [9].
Once concentration maximum of liposomes in tumor tis-
sue is achieved, circulating liposomes may contribute to
the observed adverse effects, but they may have little
further therapeutic value.
PLD has been used worldwide for many years. While the
cardiotoxicity of doxorubicin is considerably reduced,
severe skin toxicity occurs due to the unique pharmacoki-
netics of long circulating liposomes [10]. With an
approved monotherapy dosage of 50 mg/m
2 every 4 weeks
(50q4wks), approx. 50% of the patients showed palmar-
plantar erythrodysesthesia (PPE, also called hand-foot-syn-
drome) grade 1, and 20% suffered grade 3 and higher [11].
PPE correlated significantly with plasma-t1/2 [12], indicat-
ing a slow process. In mouse models, the maximum con-
centration of doxorubicin (Cmax) in tumor tissues was
reached within~24 h, while the maximum concentration
in skin and paws was attained after~72 h [7]. Thus there is
a distinct time gap in PLD accumulation between tumor
tissue and side-effect tissues. Due to the long plasma-t1/2,
about 70% of administered PLD were still circulating in
the plasma 24h after infusion. The concept of Kinetic Tar-
geting takes advantage of distinct accumulation kinetics
and long plasma-t1/2 of PLD by eliminating a major frac-
tion of circulating DDS once accumulation in tumor tissue
has reached its maximum [9].
Size exclusion filtration is the most suitable elimination
principle for eliminating various DDS [13], and the respec-
tive clinically-used elimination technique known as dou-
ble-filtration plasmapheresis (DFPP) is well suited for
eliminating PLD [14].
. In DFPP, the first filtration step
separates blood cells from plasma, while a second filtration
eliminates particles and high molecular weight compo-
nents. The system operates continuously. Elimination effi-
cacy depends on the treated plasma volume. On average it
takes about 2-3 h to treat one plasma volume and to elimi-
nate~60-70% of circulating particles [15].
This paper describes the first pilot study investigating
the concept of Kinetic Targeting. The safety and effi-
ciency of extracorporeal elimination of PLD were
addressed in the CARL-trial (Controlled Application and
Removal of Liposomal chemotherapeutics) as primary
endpoints, and side effects and tumor outcomes were
evaluated as secondary endpoints as well.
Methods
Patients and Study design
This study was conducted on patients with recently diag-
nosed primary breast cancer or in patients with recurrent
gynecological cancer aged between 18 and 70 years. Their
Eastern Cooperative Oncology Group (ECOG) perfor-
mance status had to be ≤2 and peripheral veins had to per-
mit access of apheresis catheters. Patients were excluded
for previous chemotherapy with PLD, extracorporeal treat-
ments or chemotherapeutic drugs other than those pro-
posed. Further exclusion criteria were pregnancy, severe
liver, kidney or hematopoetic dysfunction; acute or chronic
skin diseases, cachexia/BMI < 20, or acute infection.
This study was conducted as investigator-initiated trial,
sponsor was the University Freiburg Medical Center,
Dept. of Clinical Chemistry. The study was approved by
the Ethics Committee of the University Freiburg (EK-Frei-
burg 171/07). Written informed consent was provided by
all patients prior to participation. The study was registered
as DRKS00000163 in the German Registry of Clinical Stu-
dies. Participating centers were the University Freiburg
Medical Center and St. Josefs Hospital Offenburg. Due to
the trial’s design, patients were not randomized.
In treatment schedule 1 (TS1), patients with primary
breast cancer were treated prior to surgery (neoadjuvant)
with 4 consecutive cycles every 3 weeks. Each cycle con-
sisted of vinorelbine (Navelbine
®)2 5m g / m
2 on days
1 and 8, and PLD (Caelyx
®)4 0m g / m
2 on day 15. Plasma-
pheresis was performed on day 17, 42 - 48 h after infusion
of PLD. After two cycles, tumor size was measured by
magnetic resonance tomography (MRT), and the therapy
was terminated in case of no tumor reduction. Patients
who were HER2/neu-receptor positive additionally
received trastuzumab (Herceptin
®) 2 mg/kg/week. Since a
small amount of IgG is eliminated during DFPP, IgG in
plasma was measured pre-and post-plasmapheresis and
the next dosing of trastuzumab was adjusted to the
amount of eliminated IgG.
In treatment schedule 2 (TS2), patients with recurrent
ovarian or endometrial cancer received PLD (Caelyx
®)
40q4 wks. Plasmapheresis was performed 44 - 48 h after
PLD infusion. Computer tomography (CT) scans were
performed every 3 cycles. Response was classified by
Response Evaluation Criteria In Solid Tumors (RECIST)
[16] and by monitoring tumor marker CA-125.
Primary endpoints were efficiency and safety of DFPP.
Efficiency was determined by the eliminated amount of
doxorubicin. Overall efficiency was correlated to the initial
plasma concentration after infusion of PLD, while DFPP
efficiency was correlated to the concentration of circulat-
ing PLD at plasmapheresis onset. Doxorubicin in plasma
was measured according to the method of Charrois &
Allen [7]. Briefly, 500 μl of plasma were diluted with 1 ml
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Page 2 of 11of water, 500 μl of 10% (v/v) Triton X-100 and 5 ml of
acidified isopropanol (0.75 N HCl) were added. After mix-
ing, the tubes were kept at -22°C for approx. 12 h, then
mixed thoroughly and centrifuged at 12.5000 × g for
30 min. Doxorubicin fluorescence was measured using a
luminescence-spectrometer LS 50 (PerkinElmer LAS
GmbH, Rodgau, Germany). Excitation wave length was
475 nm, emission was detected at 555 nm, slit width was
10 nm.
Criteria for the safety of DFPP were leakage of doxorubi-
cin during filtration and occurrence of plasmapheresis-
related side effects. Secondary endpoints were side effects,
tumor response and quality of life. Side effects were classi-
fied according to international guidelines (CTCAEv3). To
assess quality of life (QoL) the EORTC-QLQ-C30 ques-
tionnaire was used [17]. The questionnaire was completed
prior to chemotherapy and after the last cycle. Scoring was
done according to the EORTC guidelines. Data were
assessed and scored using the Stata
® statistical package
Version 11.0 (Statacorp, Texas, USA). To assess the
impact of plasmapheresis, a custom-made questionnaire
was used (see Table 1).
Total cholesterol was measured enzymatically by
CHOD-PAP (DiaSys Diagnostic Systems GmbH, Holz-
heim, Germany), LDL and HDL-cholesterol were esti-
mated by lipoprotein electrophoresis on SAS Gel Systems
(Helena Biosciences, Gateshead, United Kingdom). Plasma
protein levels were measured by colorimetric essays (total
protein and albumin) or immunological essays (transfer-
ring, ferritin, IgG) on a Modular P (Roche Diagnostics
GmbH, Mannheim, Germany). CA-125 was measured by
immunological essay on a Cobas E 601 platform (Roche).
Plasmapheresis
As medical device a HF-440 system (Infomed s.a., Genf,
Switzerland) or an Octo Nova system (Diamed Medizin-
technik GmbH, Cologne, Germany) were used. The filter
LF 050 (Infomed) or Plasmaflow OP-05W(L) (Asahi
Medical Co. Ltd., Tokyo, Japan) were used as plasmase-
parator, and Evaflux 5A or Cascadeflow EC-50W (both
manufactured by Kawasumi Laboratories Inc. Tokyo,
Japan) were used as particle filter. They showed no differ-
ences in performance and are assumed to be identical [14].
The plasma volume to be treated was projected to 3 l. In
order to estimate efficiency and safety of the different filtra-
tion steps, doxorubicin concentrations in plasma, in the
plasma circuit post first filtration step and post second fil-
tration step were measured. Samples were taken prior to
plasmapheresis and from every 0.5 l of treated plasma
volume. The plasmapheresis system returned the plasma
and blood remaining in the extracorporeal unit to the
patient once treatment was finished, and the final blood
concentration of doxorubicin was measured thereafter.
Patients received 2 × 4000 IU heparin as bolus prior to
plasmapheresis and 3400 IU heparin/h during plasmapher-
esis. Heparin infusion was stopped~30 min prior to termi-
nating plasmapheresis.
Mathematics and Statistics
Efficiency of plasmapheresis
Blood was drawn once the infusion of Caelyx was termi-
nated and prior to the plasmapheresis treatment, and
plasma-t1/2 was calculated according to a monophasic
elimination characteristic off i r s to r d e r[ 2 ] .T om e a s u r e
the overall efficiency of plasmapheresis, doxorubicin con-
centration in plasma was estimated immediately prior to
the onset of plasmapheresis (caphstart) and after terminating
plasmapheresis (caphend). To calculate the eliminated frac-
tion of the total doxorubicin dose, concentration of doxor-
ubicin in plasma immediately after infusion of PLD was
estimated (c0). Eliminated fraction of total dose (in per-
cent) was calculated by equ. 1, eliminated fraction of circu-
lating dose was calculated by equ. 2.
Etotal =
caphstart − caphend
c0
· 100 [%] (1)
Ecirculating =
caphstart − caphend
caphstart
· 100 [%] (2)
AUC of PLD
The area under the plasma concentration curve (AUC) of
doxorubicin was calculated for each cycle (figure 1B).
Plasma-t1/2 of PLD until plasmapheresis was calculated
by c0 and caphstart. The (hypothetical) AUC without plas-
mapheresis was calculated according to c0 and estimated
plasma-t1/2 for the full length of the cycle. AUC with
plasmapheresis was calculated according to c0 and
plasma-t1/2 until the start of plasmapheresis and accord-
ing to caphend from the end of plasmapheresis until the
next cycle (for details see additional file 1).
Table 1 Patients treated for primary breast cancer
n1 2
Age (median and range) 53 (39-67)
Staging
IIA 2
IIB 4
IIIA 2
IIIB 4
Receptor
ER/PR +/+ 4
ER/PR +/- 6
ER/PR-/- 2
HER2/neu + 6
Staging was done according to the American Joint Committee on Cancer TNM
system. ER: Estrogen receptor; PR: progesterone receptor
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Figure 1 Apheresis of liposomal doxorubicin. Chart A shows the concentration of doxorubicin during plasmapheresis in blood (red line), in
the separated plasma prior to particle filtration (blue line) and post-particle filtration (black line). The insert shows a schema of the double
filtration plasmapheresis used. Blood circuit is red and plasma circuit is yellow. First filtration separates plasma from blood cells, second filtration
step eliminates particles. The plasmapheresis system returns the plasma and blood remaining in the extracorporeal unit to the patient once
treatment is finished, and final blood concentration of doxorubicin was measured thereafter. Average blood flow rates were between 50 and 65
ml/min. A typical plasmapheresis is shown (n = 57). Chart B shows the estimated area under the plasma concentration curve (AUC) for liposomal
doxorubicin without plasmapheresis (below dashed line) and with plasmapheresis (gray).
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Patients
Between February 2008 and November 2010, and 15
patients were enrolled. Patient age was between 39
and 67 years (median 53). Of 15 patients in this study,
12 patients were treated for breast cancer. Their charac-
teristics are shown in table 1, 6 patients were HER-2-
neu positive and received trastuzumab additionally. Due
to no response or persistent inflammatory disease, one
patient received only 2 and one patient only 3 cycles of
chemotherapy. All other 10 patients underwent 4 cycles
of TS1. In TS2, 2 patients showed progressive disease
after the 3rd cycle and were switched to an alternative
regimen; 1 patient with recurrent ovarian cancer
regressed and received 6 cycles of TS2. All cycles were
delivered as planned.
Plasmapheresis
A total of 57 plasmapheresis treatments were performed,
with 56 treatments achieving the projected plasma volume.
One plasmapheresis treatment had to be terminated pre-
maturely due to clotting in the vein-access catheters. All
other treatments went smoothly. Average blood flow rates
of the therapies were between 50 and 65 ml/min. A typical
plasmapheresis treatment is shown in figure 1A. Blood
concentration dropped nonlinearly due to continuous
reperfusion. The concentration of doxorubicin in plasma
was equal to the respective blood concentration, indicating
that liposomes pass the plasma filter membrane without
restriction. In contrast, the doxorubicin concentration
post particle filter was close to baseline, indicating that all
liposomes were retained in the second filter system. Most
importantly, no doxorubicin was leaking out of the lipo-
somes during the filtration process.
The average elimination characteristics of doxorubicin
are given in table 2. Plasmapheresis onset was 42-48 h
(average 46 h) after terminating the PLD infusion. At that
time point,~72% (± 6%) of the initial doxorubicin dosage
were found in circulation. About 62% (± 9%) of the circu-
lating PLD were eliminated by extracorporeal purification
of 3l of plasma, yielding an average elimination of 45%
(± 7%) of the total doxorubicin dose. Thus plasmapheresis
of PLD can be considered very efficient under the condi-
tions applied.
Elimination of lipoproteins and main plasma proteins
were measured as well (see table 3). Elimination of
plasma lipids and proteins was in the normal range for
DFPP by the materials used [18]. Within the 3-4 weeks
until the next plasmapheresis, plasma levels of lipids and
proteins had reached their initial value, and no general
decline occurred during the 4 to 6 cycles of chemother-
apy. In general, plasmapheresis was tolerated very well,
with only one plasmapheresis-related side effect, namely
a mild drop in blood pressure, during 57 treatments.
Doxorubicin pharmacokinetics
Cmax of doxorubicin post-infusion was 34 ± 5 μM. The
overall plasma-t1/2 of PLD was 93 (± 12) h, slightly above
earlier data [2]. In order to restrict total blood loss for
patient safety, pharmacokinetics were estimated by the
most essential data points only, and the discrepancy in
plasma-t1/2 to previous published data is probably due to
few data points available. Mean plasma-t1/2 were
90 (± 18), 93 (± 17), 105 (± 25) and 119 (± 37) h for cycle
1 to 4. Of 11 patients receiving > 3 cycles, 6 showed a con-
secutive progression of plasma-t1/2,w h i l e5p a t i e n t s
showed no tendency for prolonged plasma-t1/2.T h e
reduction in total doxorubicin dosage was 45%. Impact of
plasmapheresis on AUC was roughly estimated for each
cycle by the measured plasma-t1/2 and DFPP efficiency
(details see additional file 1). AUC with plasmapheresis
w a s5 0 %( ± 3 % )o ft h ec a l c u l a t e dA U Cw i t h o u tp l a s m a -
pheresis (figure 1B)
Toxicity
The most remarkable result of the CARL pilot trial was
t h eo c c u r r e n c eo fas i n g l eg r a d e2P P Ee v e n td u r i n g
57 cycles of PLD (figure 2). The same patient reported
a grade 1 exanthema, the only reported exanthema dur-
ing the trial. This result is even more remarkable as
the average dosage of PLD was slightly higher in TS1
(13,3 mg/m
2/week) than in the standard regimen 50q4
wks (12,5 mg/m
2/week). Side effects were graded
according to CTCAEv3 guidelines, parentheses show the
Table 2 Elimination of doxorubicin by double filtration plasmapheresis
Cmax of doxorubicin post infusion 34 ± 5 [μM]
Doxorubicin at plasmapheresis onset 72 ± 6% [% of Cmax]
Doxorubicin at plasmapheresis termination 28 ± 9% [% of Cmax]
Elimination of total doxorubicin 45 ±7% [% of total doxorubicin dose]
Elimination of doxorubicin in plasma 62 ± 9% [% of plasma doxorubicin at plasmapheresis initiation]
Reduction in AUC 50 ± 3%
A total of 57 apheresis treatments were conducted. Treated plasma volume was 3 l, plasmapheresis was initiated~46 h after PLD infusion was terminated.
Concentration of doxorubicin in plasma was measured immediately after infusion (cmax), at apheresis onset and when apheresis was terminated. The eliminated
amount of total doxorubicin dosage (line 4) and of circulating liposomal doxorubicin at apheresis onset (line 5) is given. The AUC was calculated as described in
methods, and the reduction in AUC of doxorubicin by apheresis is stated. Data are mean ± SD.
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Page 5 of 11numbers of cycles affected and the respective percentage
according to the total number of cycles in TS1 or TS2.
In TS1 mucositis/stomatitis grade 1 were reported by 4
patients (8 cycles, 18%), and grade 2 by 1 patient in 1
cycle (2%). Six patients reported fatigue (12 cycles, 27%)
in TS1 and 2 patients (4 cycles, 33%) in TS2. Alopecia
was reported after 2 cycles (4%) by 1 patient in TS1.
One patient in TS2 presented grade 1 obstipation during
Table 3 Elimination of plasma lipids and proteins
Plasma component plasma level (prior to plasmapheresis) elimination [%]
Lipids
Total cholesterol 193 ± 33 [mg/dl] 46 ± 8
LDL-cholesterol 104 ± 27 [mg/dl] 59 ± 10
HDL-cholesterol 57 ± 22 [mg/dl] 10 ± 8
Proteins
Total protein 6,7 ± 0,3 [g/dl] 16 ± 3
Albumin 4,2 ± 0,2 [g/dl] 13 ± 4
Transferrin 233 ± 30 [ng/dl] 12 ± 4
Ferritin 152 ± 115 [ng/dl] 22 ± 7
IgG 848 ± 144 [mg/dl] 18 ± 5
Plasma levels were measured by standard clinical chemistry methods immediately prior and past plasmapheresis. Fasting was not required prior to
plasmapheresis, so total cholesterol, LDL-cholesterol and HDL-cholesterol could not be accurately estimated in all cycles (n = 32-57). All values are mean ± SD.
Mucositis total
Mucositis III
PPE total
PPE III
Neutropenia total
Neutropenia IV
0 1 02 03 04 05 06 07 08 09 0 1 0 0
Percentage of Patients
Martin et al. Burstein et al CARL-Trial
?/34
13/21
8/21
15/34
6/12
0/12
17/34
26/34
5/34
2/34
1/12
0/12
0/12
7/21
1/21
9/21
6/21
5/12
grade I-III not reported
(and number affected/total)
Figure 2 Major toxicities observed during the CARL trial and related published trials. The major levels of toxicity for different treatment
schedules using a combination of PLD and vinorelbine are given as percentage of patients and as number of patients/total patients in trial.
Grading according to CTCAEv3-criteria is given in Roman numerals. Black bars: study of Martin et al. (n = 34), vinorelbine 30 mg/m
2 and PLD 35
mg/m
2 every 4 weeks [20]; red bars: study of Burstein et al. (n = 21), vinorelbine 2 × 25-30 mg/m
2 and PLD 40-50 mg/m
2 every 4 weeks [19]; blue
bars: CARL-Trial (n = 12), vinorelbine 2 × 25 mg/m
2 and PLD 40 mg/m
2 + plasmapheresis every 3 weeks. Unfortunately, the frequency of
neutropenia < grade IV is not reported in the study of Martin et al.. PPE = palmar-plantar erythrodysesthesia, PLD: pegylated liposomal doxorubicin.
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Page 6 of 113 cycles, another patient had diarrhea during 1 cycle and
nausea grade 1 after the first PLD infusion. In TS1, six
patients had grade 1 leucopenia (17 cycles, 38%) while
two patients had grade 2 leucopenia during 3 cycles
(7%). Four patients suffered neutropenia grade 1 (11
cycles, 23%), and one patient grades 2 and 3 (1 cycle
each, 2%). In TS2, no hematological toxicology was
reported. No significant increase in safety parameters
and proBNP-levels were monitored during the study
except for a slight increase in liver enzymes (grade 1)
during 1 cycle in TS2.
Response
One reason to include patients with neoadjuvant treat-
ments in this pilot study was the opportunity to assess
the size of the primary tumor as a direct readout of clini-
cal response. Of 12 patients included on TS1, 10 patients
showed a response. Nine patients had a significant reduc-
tion of tumor size > 50%, with two patients > 90%. Aver-
age tumor size reduction was~70%. Breast-conserving
surgery was successful in 6 patients who completed TS1.
For the three patients with a gynecological tumor on
TS2, one showed remission and a decline in CA-125
from 99 to 75 U/ml while 2 patients showed progredient
lesions and an increase in CA-125.
Quality of life and acceptance
To address the impact of chemotherapy on QoL, the
questionnaire QLQ-C30 [17] was completed after the
first and last cycles. Altogether 10 patients were eligible
for data assessment, 9 patients after 4 cycles (TS1) and 1
patient after 6 cycles (TS2). The results are shown in
figure 3. Due to the low number of patients, a statistical
analysis was not feasible. In general, functional scores
remained high during chemotherapy (all medians > 50%),
while all symptom scores remained low (all medians
< 50%) While the medians of the functional parameters
remained more or less unchanged during chemotherapy,
few individual scores declined as indicated by a wider
range in percentiles. Interestingly, global health status
and overall QoL did not change between first and last
cycles according to the patients’ self-ssessment. In gen-
eral, the combinations of PLD and plasmapheresis only
had a slight impact on patient-reported QoL. To evaluate
the impact of extracorporeal treatment during che-
motherapy in more detail, we used a customized ques-
tionnaire. In general, most of the patients felt well, prior
to, during and after plasmapheresis (see table 4).
Discussion
The CARL trial is the first clinical trial to investigate the
principle of Kinetic Targeting by combining DFPP and
PLD. DFPP has been used in clinical practice for years
to eliminate natural plasma components. PLD is the
most widespread anticancer drug using a nanoscale
DDS, and has a very favorable pharmacokinetic profile
for Kinetic Targeting. Besides monotherapy, PLD has
been successful in various combinations, and the combi-
nation of vinorelbine and PLD has proven to be highly
efficacious with tolerable side effects [19,20]. PLD was
initially approved as monotherapy 50q4 wks, but due to
the fear of side effects, a lower dosage of 40q4 wks is
commonly used in clinical practice [21]. In this study, a
low dose monotherapy (TS2) in recurrent disease and a
dose-intensive combination of vinorelbine and PLD as
neoadjuvant treatment were evaluated (TS1). Since first
treatments on TS1 showed minimal side effects, the
ongoing study focused on the dose-intensive treatment,
and a total of 12/15 patients were enrolled on TS1. The
protocol for TS1 was based on a protocol investigated
in the study center in Offenburg, containing 35 mg/m
2
PLD on day 15. Despite Kinetic Targeting, plasmapher-
esis may reduce the amount of accumulated drug in
tumor slightly. When a model calculation was per-
formed (see additional file 2), a dosage 40 mg/m
2 +
plasmapheresis showed higher Cmax in tumor than a
dosage of 35 mg/m
2 without plasmapheresis. Beside
Cmax, AUC in tumor rose by~2%, while Cmax and
AUC in skin fell by~20%. Thus the dosage used in TS1
was raised to 40 mg/m
2 PLD.
Primary endpoints of the CARL pilot trial were the effi-
ciency and safety of PLD elimination by DFPP. Just one
mild plasmapheresis-related side effect was noted in 57
plasmapheresis treatments. Efficiency of PLD elimination
was as high as known for other DFPP procedures. Most
importantly, neither liposomal nor free doxorubicin were
detected in the plasma beyond the particle filter, indicat-
ing that PLD can be filtered without leakage even after
prolonged circulation in vivo. Safety and efficiency of
PLD elimination by DFPP were considered excellent in
this trial.
The most striking result of the CARL pilot trial was the
occurrence of a single grade 2 PPE during 57 cycles of
PLD. Interestingly, the elimination efficiency for the
patient reporting PPE after the 3
rd cycle was significantly
below average (32-36% of total dose). The pilot study data
are even more promising since 12 patients received 13,3
mg/m
2/week of doxorubicin in a combination therapy,
slightly more than the recommended dosage for mono-
therapy (12,5 mg/m
2/week). At recommended dosage,
approx. 50% of the patients showed PPE grade 1 and 20%
grade 3 and higher [11]. In a combination of vinorelbine
and PLD 35q4 wks, 49% developed PPE and 62% mucosi-
tis [20]. Furthermore, the maximum tolerated doses for
PLD in different combination therapies on a 3-doses-a-
week schedule were 30 mg/m
2 [22], 35 mg/m
2 [23] or
45 mg/m
2 with PPE/mucositis occurring at 40 mg/m
2
[24]. Besides one grade 2 PPE only five grade 2 and one
Eckes et al. BMC Cancer 2011, 11:337
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Insomnia Appetite loss
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B
Figure 3 QLQ-C30 Scores. To address quality of life during chemotherapy, the QLQ-C30 questionnaire was used [17]. The scores were
calculated according to the manual. The questionnaire was filled after the first cycle (timepoint 1) and after the last cycle (timepoint 2), 10
patients were eligible completing 4 (n = 9) or 6 (n = 1) cycles. (A) Functional scores (high score corresponds to high functionality) (B) Symptom
scores (low score correspond to mild symptoms).
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Page 8 of 11grade 3 events were observed during 45 cycles of the dose-
intense TS1 in the CARL-trial. No dose modification or
any delay was necessary to manage toxicity. In combina-
tion with plasmapheresis, PLD at a higher dosage than ori-
ginally recommended for monotherapy was very well
tolerated in combination with vinorelbine. In the low
dosage TS2, we noted only minor side effects and just
grade 1 events. While antitumor efficacy is correlated to
Cmax [6], PPE correlated significantly to plasma-t1/2 [12].
DFPP induces a significant cut in plasma-t1/2,a n dt h e
observed absence of PPE is well in line with these prior
observations. In a certain sense, CARL may be considered
as a means of cutting plasma-t1/2 while keeping Cmax
constant.
Most patients accepted plasmapheresis treatment very
well, as reflected in the questionnaires (table 4).
In TS1, response was observed in 10/12 patients, and
9/12 patients experienced a tumor size reduction > 50%,
in line with other highly efficient anthracycline contain-
ing protocols in neoadjuvant treatment of breast cancer
[25-27]. Response rates in recurrent platinum-resistant
ovarian cancer with PLD 40q4 wks as second line treat-
ment are generally low [28]. With 3 patients in TS2, we
observed one partial response. These data indicate that
PLD was still active on the low dosage schema despite
scheduled extracorporeal elimination of circulating drug.
While the reduction of side effects was apparent, we
cannot address therapeutic efficacy due to this pilot
trial’s small cohort. A randomized phase II trial with
sufficient statistical power is clearly needed to address
this question.
Within the breast cancer group, 6/10 patients were
HER2/neu-positive and received trastuzumab. The combi-
nation of trastuzumab and PLD has shown encouragingly
low cardiac toxicity in these patients, but also an elevated
incidence of PPE. Combining trastuzumab with PLD at
50q4wks, the incidence for PPE grades 1-2 was 37% and
for PPE grade 3 even 30% [29]. PLD at 40q4wks led to
PPE grades 1 and 3 in 12,5% of patients respectively [30].
A combination of trastuzumab with PLD (30 mg/m
2) and
docetaxel (60 mg/m
2) every 3 weeks led to 75% PPE (38%
grade 3) [26]. Combining these data and the lack of any
PPE in our 6 patients receiving high dosage of PLD
and trastuzumab, patients with HER2/neu-positive meta-
static breast cancer may have an additional significant
benefit by using a combination of trastuzumab, PLD, and
plasmapheresis.
The approved dosage for PLD monotherapy is 50q4wks,
b u ti tw a sa s s u m e dt h a tar e d u c e dd o s a g eo f4 0 q 4 w k s
would reveal less toxicity while maintaining clinical effi-
cacy [21]. While the benefit in side effects seems obvious,
the assumption of maintaining clinical efficacy was based
on two retrospective studies and a single phase-II prospec-
tive trial with a very low response rate (9%) [24]. All those
studies were performed on patients with recurrent ovarian
cancer who generally show a low response rate. The ratio-
nale behind the dose reduction was an obvious improve-
ment in quality of life, while any impact on clinical benefit
remained hidden behind the curtain of statistical power.
O nt h eo t h e rh a n d ,a ne a r l ys t u d yb yM u g g i ae ta l .[ 3 1 ]
showed a high response rate (27%) for patients with plati-
num -resistant recurrent ovarian cancer using a high
dosage of 50q3wks, but they also found an intolerable inci-
dence of side effects, mainly PPE and stomatitis. Although
there is no prospective study comparing 50 to 40 mg/m
2,
the lower dosage has been widely accepted in clinical prac-
tice due to the fear of PLD side effects. Kinetic Targeting
is a much smarter variant of dose modification, and due to
this trial’s data, we propose a smarter way of minimizing
toxicity and a lesser impairment of clinical efficacy by
CARL than by a simple dose reduction. Correlating tumor
response to dosage is often difficult. PLD accumulation in
tumor tissue is strictly dependent on Cmax [5,7,32]. In
patients with Kaposi’s sarcoma, average peak plasma con-
centrations as well as dose intensities have been found to
correlate very closely with anti-tumor response [6]. The
same was seen in animal models, where a single bolus was
more effective than administrating equal amounts of drug
in split portions [32,7]. Thus reducing the recommended
dosage in mono- or combination therapy is probably paid
by disproportionate high reduction in anti-tumor efficacy
[33]. Given the diminished incidence of PPE in this trial,
maintaining recommended dosage in combination thera-
pies or even a more intensive dosage in monotherapy
Table 4 Questionnaire Plasmapheresis
How did you feel ... very good good moderately poor
- prior to plasmapheresis 1 36 11 2
- during plasmapheresis 1 40 7 2
- immediately after plasmapheresis 1 41 6 2
in between plasmapheresis and next cycle (not assessed after last cycle) 0 25 9 2
no little moderate high
Classify your effort for plasmapheresis treatment today 8 25 10 7
To asses any direct impact of plasmapheresis on Quality of life, a custom-made questionnaire was given to the patients after each cycle. 50 cycles in total were
evaluated. No significant change between different cycles became apparent.
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Page 9 of 11might become feasible (e.g. 50q3wks) and should be evalu-
ated in future.
Severe side effects often cause the next cycle to be
delayed, even though maintaining dosage is crucial for
therapeutic success. In the study of Burstein et al. [19],
18/73 cycles were delayed or vinorelbine omitted, and
7/18 patients required a dose reduction in the cohort
receiving PLD 40q4wks. In the study reported by Lyass
et al, [12] only~25% of patients received the fourth dosage
on time when PLD was given as monotherapy 35q3wks.
Within the CARL trial, all patients received their recom-
mended dosage on time, even though 45 cycles were given
on the dose-intense TS1. Keeping chemotherapy on sche-
dule is another likely benefit of CARL, probably improving
the clinical efficacy of the proposed treatments.
The CARL trial is the first clinical trial investigating the
principle of Kinetic Targeting, and demonstrating the
feasibility of this approach. We used currently available
and approved materials and DDS. DFPP is based on size
exclusion, and is generally applicable for all kinds of nano-
particle based DDS having the appropriate size between
approx. 500 and 25 nm. Fortunately, the nanoparticles
used in anticancer treatment are usually in that size range
[34]. For Kinetic Targeting a long plasma-t1/2 is needed,
a basic feature of most nanoparticles investigated so far,
and the technique used should be applicable with a broad
range of nanoparticle-based DDS. PLD is optimized in
terms of plasma-t1/2, but not regarding the bioavailability
of drug delivered to the tumor. Several improved DDS are
being investigated preclinically, and some in clinical trials
[34]. All these approaches deal with the DDS reaching the
tumor, but CARL deals with the major fraction of DDS
not reaching the tumor. Thus we propose that CARL may
prove especially valuable with future DDS, revealing
improved targeting and release properties.
Conclusion
DFPP is an efficient and safe technique to eliminate PLD
during chemotherapy. The combination of PLD and DFPP
allowed successful therapy and a clearly favorable side-
effect profile. In contrast to a simple dose reduction, the
concept of Kinetic Targeting enables profound drug elimi-
nation at a time point when the impact on adverse toxicity
is likely to be much greater than the impact on tumor
toxicity.
Additional material
Additional file 1: Estimation of AUC. This file contains a detailed
description about the calculation of AUC.
Additional file 2: Model calculation about the impact of
plasmapheresis. This file contains a model calculation based on the
data known from animal studies [7]. The model tries to simulate the
impact of plasmapheresis on tumor accumulation of PLD. Two scenarios
were calculated, one scenario regarding the EPR-effect and one scenario
using a simple equilibrium model.
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